UCBJY News and Press, UCB S.A. ADR From 04/24/24

2024-04-24 10:00:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio meaningfully beat the benchmark MSCI EAFE Index, as well as the seconda...

2024-04-24 09:30:00 ET Summary Artisan Partners is an independent investment management firm focused on providing high value-added, active investment strategies to sophisticated clients globally. The portfolio solidly outperformed the MSCI AC World Index. Holdings in health ca...

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting PR Newswire Diverse and patient-focused data set comprises 17 abstracts including one oral presentation Features new data analyse...

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa PR Newswire Campaign offers resources and information about hidradenitis suppurativa (HS) and amplifies diverse patient voices and stories to reach p...

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations PR Newswire Application in moderate-to-severe hidradenitis suppurativa based on results from two...

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis PR Newswire Late-breaking platform presentation showed that BIMZELX ® (bimekizumab-bkzx) rapidly achieved ...

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count PR Newswire Patients treated with BIMZELX ® (bimekizumab-bkzx) demonstrated clinically meaningful improvements in...

UCB on Growth Path for a Decade Plus PR Newswire Revenue in 2023 reached € 5.25 billion (-5%; -6% CER 1 ), net sales were € 4.87 billion (-5%; -6% CER 1 ) – in-line with financial guidance Strong performance by newly launched growth drivers (ne...

2024-02-01 07:22:58 ET Summary Vyvgart generated $1.2 billion in net sales in 2023 and is in a good position to continue performing well in 2024 and beyond. Empasiprubart has generated strong results in the first cohort of MMN patients, putting this candidate on investors' radars ...

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive PR Newswire ZILBRYSQ ® (zilucoplan) is now commercially availa...